Senti Biosciences’ (SNTI) Buy Rating Reaffirmed at Chardan Capital
Senti Biosciences (NASDAQ:SNTI – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a report released on Thursday,Benzinga reports. They presently have a $12.00 price target on the stock. Chardan Capital’s price objective points to a potential upside of 361.54% from the company’s previous close. Separately, Laidlaw began coverage […]
Senti Biosciences (NASDAQ:SNTI – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a report released on Thursday,Benzinga reports. They presently have a $12.00 price target on the stock. Chardan Capital’s price objective points to a potential upside of 361.54% from the company’s previous close. Separately, Laidlaw began coverage […]
